MicroRNA-744 promotes proliferation of osteosarcoma cells by targeting PTEN

Introduction

MicroRNAs (miRNAs/miRs) are a class of small, non-coding single-stranded RNAs that either repress translation or degrade mRNA by base pairing to the 3′ untranslated region (3′UTR), thus contributing to inhibition of target gene expression (1,2). miRNAs are involved in various physiological and pathological processes, including carcinogenesis, cell proliferation and differentiation (2). Moreover, it has been reported that miRNA alterations are associated with the initiation, progression and metastasis of human cancer (3,4). Osteosarcoma is a common primary malignant bone tumor mainly occurring in childhood and adolescence, which has a high mortality rate, with a 5-year survival rate of <60%, due to robust invasion and metastasis (5). While treatment for osteosarcoma has progressed, the prognosis of osteosarcoma remains poor, with a relatively unchanged 5-year survival rate of 65% over the last 30 years (6). Furthermore, the pathogenesis of osteosarcoma is not fully understood.

Abnormal miRNA expression may be involved in the occurrence and development of osteosarcoma. It has been reported that miR-144 suppressed tumor growth and metastasis in osteosarcoma via dual-suppression of the Ras homolog family member A and Rho-associated coiled-coil-containing protein kinase 1 signaling pathways (7). However, miR-181a and miR-199b-5p have been shown to promote cell proliferation, invasion and metastasis in osteosarcoma (8,9). Furthermore, a recent study identified the involvement of miR-744 in osteosarcoma and chemotherapy resistance (10). Sun et al (11) revealed that miR-744 promoted osteosarcoma development and progression by suppressing large tumor suppressor kinase 2 (LATS2) signaling. However, due to the limited number of studies examining miR-744 in osteosarcoma, the role of miR-744 and its underlying molecular mechanisms in the pathogenesis of osteosarcoma are not fully understood. PTEN, a unique tumor suppressor gene, has been identified to be a targeted gene of miR-744 in laryngeal squamous cell carcinoma (12), and has also been shown to be associated with the growth and metastasis of various malignant tumors (13). Therefore, the aim of the present study was to investigate whether PTEN is a direct target of miR-744 in the regulation of osteosarcoma cell proliferation.

Materials and methods

Cell culture and tissue samples

The MG63, U2OS and SaOS2 human osteosarcoma cell lines were obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The hFOB1.19 human fetal osteoblastic cell line was obtained from the Institutes for Biological Sciences, Chinese Academy of Sciences. Human osteosarcoma cell lines were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.), and the human fetal osteoblastic cell line was cultured in DMEM-F12 medium (Gibco; Thermo Fisher Scientific, Inc.). The aforementioned media were supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Cells were maintained and subcultured at 37°C in a humidified incubator containing 5% CO2. Cells were pre-treated with 0.1% DMSO (control) or 20 µM LY294002 (dissolved in 0.1% DMSO; Sigma-Aldrich; Merck KGaA) for 8 h at 37°C.

In total, 25 osteosarcoma tissue samples and corresponding adjacent non-tumor tissues (>2 cm from the tumor margin) were obtained from the Department of Orthopedic Surgery, The Second Affiliated Hospital of Wenzhou Medical University. Tissue samples were collected from patients undergoing complete resection surgery between July 2015 and June 2019. Informed consent was obtained from the patients (age, ≥18 years) or their parents (patients aged <18 years), and all patients had not received any radiation therapy or chemotherapy prior to surgery. The samples were obtained from 15 male patients and 10 female patients (age, 23.6±8.6 years; age range, 12–43 years) with an average tumor size of 8.7±3.5 cm (tumor size range, 3.8–16.1 cm). With regards to tumor subtype, 21 were high-grade osteosarcoma, one was intermediate-grade osteosarcoma and three were low-grade osteosarcoma. WHO classification was used to identify the osteosarcoma subtypes based on the characteristics of tumor tissue observed under the microscope (14). This study was approved by the Ethics Committee of The Second Affiliated Hospital, Wenzhou Medical University.

Analysis of miRNA expression using reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from tissue samples and cell lines using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. RNA was reverse transcribed into cDNA using stem-loop primers and the TaqMan miRNA RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature and duration conditions of RT were as follows: 37°C for 15 min and 85°C for 5 sec. The specific primer sequences were as follows: miR-744, forward 5′-ACACTCCAGCTGGGTGCGGGGCTAGGGCTAAC-3′, reverse 5′-CTCAACTGGTGTCGTGGA-3′; and U6 small nuclear RNA, forward 5′-CTCGCTTCGGCAGCACA-3′ and reverse 5′-AACGCTTCACGAATTTGCGT-3′. miR-744 expression was detected using a TaqMan human miRNA assay (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. qPCR was performed using an Applied Biosystems 7500 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with U6 small nuclear RNA as the internal control. The following thermocycling conditions were used: Initial denaturation at 95°C for 5 min; followed by 40 cycles at 95°C for 15 sec, and primer annealing and extension at 60°C for 30 sec; and final extension for 1 min at 72°C. The relative expression of miR-744 was calculated using the 2−ΔΔCq method (15).

Cell transfection

miR-744 precursor (5′-UGCGGGGCUAGGGCUAACAGCA-3′; final concentration, 100 nM), miR-744 inhibitor (anti-miR-744; 5′-UGCUGUUAGCCCUAGCCCCGCA-3′; final concentration, 100 nM) and their corresponding miR negative controls (miR-control; 5′-UUCUCCGAACGUGUCACGUTT-3′; final concentration, 100 nM; and anti-miR-control; 5′-CAGUACUUUUGUGUAGUACAA-3′; final concentration, 100 nM) were purchased from Shanghai GenePharma Co., Ltd. At 60–70% confluency, MG63 osteosarcoma cells were transfected for 6 h at 37°C using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were then transferred to complete medium and incubated at 37°C for 48 h before harvesting. Transfection efficiency was subsequently evaluated by RT-qPCR at 48 h after transfection. Subsequent experiments were performed at 24 h post-transfection.

Bromodeoxyuridine (BrdU) assay

Cell proliferation was assessed using an ELISA BrdU kit (cat. no. Roche-11647229001; Sigma-Aldrich; Merck KGaA). Following successful transfection, cells were seeded in 96-well plates at a density of 2×103 cells/well. The BrdU assay was subsequently performed according to the manufacturer's protocol. Absorbance was measured at a wavelength of 450 nm using an enzyme immunoassay analyzer (Bio-Rad Laboratories, Inc.). To determine the cell number, cells collected, centrifuged at 150 × g for 5 min at room temperature, resuspended and counted using a light microscope (magnification, ×400) with a Neubauer counting chamber. The experiment was repeated ≥3 times.

Western blot analysis

To isolate proteins, cells or tissues were harvested and lysed with ice-cold RIPA lysis buffer (Beyotime Institute of Biotechnology). The lysates were centrifuged at 20,000 × g for 15 min at 4°C. Proteins in the supernatants were then collected and quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein (40 µg/lane) were separated by SDS-PAGE on 10% gels, and then transferred to PVDF membranes (Bio-Rad Laboratories, Inc.). After blocking with 5% non-fat milk in TBS-Tween (TBST; 50 mM Tris-HCl; pH 7.5; 150 mM NaCl; 0.05% (v/v) Tween 20) for 2 h at room temperature, membranes were incubated with specific primary antibodies overnight at 4°C, including anti-phosphorylated (p)-PTEN (cat. no. 9554; 1:500), anti-PTEN (cat. no. 9552; 1:500), anti-p-AKT (cat. no. 4060; 1:1,000), anti-AKT (cat. no. 9272; 1:1,000) and anti-GAPDH (cat. no. 8884; 1:1,000), which were purchased from Cell Signaling Technology, Inc. After washing three times with TBST, membranes were incubated with horseradish peroxidase-linked rabbit anti-mouse secondary antibody (cat. no. A0216; 1:2,000; Beyotime Institute of Biotechnology) at room temperature for 2 h. The protein signals were detected using an enhanced chemiluminescence system western blotting kit (GE Healthcare Bio-Sciences), according to the manufacturer's protocol. The density of protein bands was semi-quantified by ImageJ software (version 1.6; National Institutes of Health) and the value was normalized to that of GAPDH.

Luciferase reporter assay

TargetScan (version 7.2; www.targetscan.org/vert_72) and miRanda (version 2010; www.microrna.org/microrna/home.do) were used to predict the target sites for miR-744, and subsequently identified binding sites between PTEN and miR-744. The predicted wild-type and mutant 3′UTRs of PTEN containing the binding sites to hsa-miR-744 were cloned by PCR amplification. Genomic DNA of MG63 cell was used as the template. PCR was performed using the Takara™ LA Taq DNA polymerase kit (Takara Bio, Inc.) with the following thermocycling conditions: Denaturation at 95°C for 5 min; followed by 30 cycles at 95°C for 15 sec; primer annealing and extension at 72°C for 30 sec; followed by 15 cycles at 95°C for 15 sec, 53°C for 30 sec, 72°C for 30 sec; and a final extension step of 10 min at 72°C. Subsequently, genes were inserted into the pMIR-REPORT luciferase vector (Applied Biosystems; Thermo Fisher Scientific, Inc.) at the SacI and HindIII sites. The following primers were used to amplify specific fragments: Wild-type PTEN forward, 5′-CCACATCCTACCCCTTTGCACTGGCAACAGATAAGTTTGCAGTTGGCTAA-3′ and reverse, 5′-AGCTTTAGCCAACTGCAAACTTATCTGTTGCCAGTGCAAAGGGGTAGGATGTGGACT-3′; and mutant PTEN forward, 5′-CCACATCCTACCCCTTTGCACCTATCGTCGATAAGTTTGCAGTTGGCTAA-3′ and reverse, 5′-AGCTTTAGCCAACTGCAAACTTATCGACGATAGGTGCAAAGGGGTAGGATGTGGAGCT-3′. For the reporter assay, all cells were seeded (1×105 cells/well) in 24-well plates. At 70% confluency, pMIR-REPORT vector (200 ng) containing the wild-type or mutant 3′UTR of PTEN, along with miR-744 precursor (200 ng) or anti-miR-744 (200 ng) were co-transfected into the cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. After transfection at 37°C for 36 h, cells were lysed using 0.25% trypsin-EDTA and the luciferase activity was determined using a dual-luciferase reporter assay system (Promega Corporation). Relative firefly luciferase activity was normalized to Renilla luciferase activity.

Statistical analysis

Experiments were repeated ≥3 times, and data are presented as the mean ± standard error of the mean. Differences between groups were analyzed using a paired Student's t-test or one-way ANOVA followed by a Tukey's multiple comparison post hoc test. Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc.) and SPSS software version 18 (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

miR-744 expression is upregulated in osteosarcoma tissues and cells

miR-744 expression in the 25 pairs of human osteosarcoma tissues and adjacent non-malignant tissues was assessed using the TaqMan RT-qPCR assay. It was revealed that the expression levels of miR-744 were significantly increased in osteosarcoma tissues compared with the adjacent non-malignant tissues (Fig. 1A). Moreover, osteosarcoma cell lines (U2OS, SaOS2 and MG63) expressed higher levels of miR-744 compared with the human fetal osteoblastic cell line hFOB1.19 (Fig. 1B). The MG63 cell line was selected for further studies as it exhibited the highest expression of miR-744 among the three osteosarcoma cell lines. Based on the overexpression of miR-744 in osteosarcoma tissues and cells, it was hypothesized that miR-744 may act as a functional miRNA in osteosarcoma, particularly in the MG63 cell line.

Figure 1. miR-744 expression is increased in osteosarcoma tissues and cell lines. (A) miR-744 expression was detected in 25 pairs of human osteosarcoma tissues and matched adjacent non-malignant tissues (Normal) using TaqMan RT-qPCR assay; U6 was used as the internal control. **P<0.01 vs. Normal. (B) miR-744 expression was detected in three osteosarcoma cell lines (U2OS, SaOS2 and MG63) and a human osteoblastic cell line (hFOB1.19) by RT-qPCR. *P<0.05, **P<0.01 vs. hFOB1.19. miR-744, microRNA-744; RT-qPCR, reverse transcription-quantitative PCR.

miR-744 enhances proliferation of osteosarcoma cells

In order to investigate whether miR-744 was involved in osteosarcoma carcinogenesis, miR-744 precursor and anti-miR-744 were transiently transfected into MG63 cells. The effects of miR-744 on osteosarcoma cell proliferation were subsequently assessed by BrdU assays. After 48 h, as determined by RT-qPCR, miR-744 was significantly overexpressed or knocked down by miR-744 precursor and anti-miR-744, respectively (Fig. 2A). Furthermore, BrdU assay results demonstrated that miR-744 overexpression significantly enhanced the proliferation of MG63 cells. However, knockdown of miR-744 significantly inhibited the proliferation of MG63 cells (Fig. 2B). Meanwhile, cell counting experiments indicated that miR-744 overexpression or knockdown resulted in significance alterations to the cell numbers within 3 days (Fig. 2C). The miR-744 overexpression or knockdown-mediated effects on cell numbers were more obvious with incubations >3 days (data not shown).

Figure 2. Effects of miR-744 on the proliferation of osteosarcoma cells. (A) Successful transfection of miR-744 precursor or anti-miR-744 in MG63 cells was assessed by reverse transcription-quantitative PCR. (B) Effects of miR-744 on cell proliferation were determined by bromodeoxyuridine assay following transfection for 24 h. (C) Proliferation curve of MG63 cells following transfection. *P<0.05, **P<0.01 vs. miR-control; #P<0.05 vs. Anti-miR-control. miR, microRNA.

PTEN is a direct target of miR-744 in osteosarcoma cells

Bioinformatics analysis using TargetScan 7.2 and miRanda suggested various potential target genes for miR-744. Of these potential candidates, PTEN, which is a tumor suppressor gene (13), harbored potential miR-744 binding sites within its 3′UTR (Fig. 3A). To further assess whether miR-744 directly targeted PTEN, a vector containing the PTEN-3′UTR was constructed and transfected into MG63 cells. It was demonstrated that the miR-744 precursor decreased luciferase activity, whereas anti-miR-744 significantly increased the luciferase activity of MG63 cells transfected with the wild-type PTEN 3′UTR (Fig. 3B). Furthermore, the protein expression of PTEN was significantly reduced by miR-744 overexpression, but significantly increased by miR-744 inhibition in osteosarcoma cells (Fig. 3C and D).

Figure 3. miR-744 negatively regulates PTEN expression in MG63 cells. (A) Predicted sequences of miR-744 binding sites in the 3′UTR of human PTEN gene. Potential binding sites are highlighted. (B) Relative luciferase activity was detected in MG63 cells following co-transfection with wild-type or mutant PTEN reporter plasmids, and miR-744 precursor or anti-miR-744. (C) Representative images and (D) semi-quantitative analysis of PTEN protein expression in MG63 cells were obtained by western blotting, following transfection with miR-744 precursor, anti-miR-744 or negative controls for 24 h. GAPDH was used as an internal control. *P<0.05 vs. miR-control; #P<0.05 vs. Anti-miR-control. 3′UTR, 3′ untranslated region; miR, microRNA.

PTEN functions as a negative regulator of the PI3K/AKT signaling pathway, which has been reported to be active in a wide range of tumor types (16–18). Therefore, the present study detected the protein expression of active AKT via western blotting in osteosarcoma cells transfected with miR-744 precursor or anti-miR-744. It was identified that miR-744 overexpression induced AKT activation in MG63 cells, whereas downregulation of miR-744 decreased P-AKT expression (Fig. 4A and B). In addition, LY294002, an AKT inhibitor, abrogated the proliferative effect induced by miR-744 overexpression in osteosarcoma cells (Fig. 4C). Collectively, the present results indicated that PTEN may be a direct target of miR-744 in osteosarcoma cells.

Figure 4. miR-744 positively regulates AKT activation in MG63 cells. (A) Representative images and (B) semi-quantitative analysis of the expression of P-AKT in MG63 cells was obtained by western blotting, following transfection with miR-744 precursor, anti-miR-744 and negative controls for 24 h. GAPDH was used as a loading control. (C) Bromodeoxyuridine assay detected the proliferative potential of MG63 cells following transfection with miR-744 precursor or anti-miR-744 for 24 h. Cells were pretreated with DMSO or 20 µM LY294002 for 8 h. GAPDH was used as an internal control. *P<0.05 vs. miR-control; #P<0.05 vs. Anti-miR-control. miR, microRNA; P-, phosphorylated; T-, total.

Discussion

Osteosarcoma, one of the most malignant types of bone cancer, is associated with rapid deterioration and metastasis, and is a major health threat to pediatric and adolescent patients (19,20). Previous studies have shown that miRNAs are involved in the regulation of various biological processes in osteosarcoma, including cell proliferation, differentiation, migration and invasion (7–9). The present results suggested that miR-744 expression was upregulated in osteosarcoma tissues and cells. Moreover, it was demonstrated that ectopic overexpression of miR-744 promoted the proliferation of MG63 cells, whereas miR-744 inhibition using antisense oligonucleotides inhibited cell proliferation.

It has been reported that miR-744 may function as either an oncogene or a tumor suppressor in different cancer types. Consistent with the present results, miR-744 was highly expressed and acted as an oncogene in pancreatic cancer (21), prostate cancer (22) and nasopharyngeal carcinoma (23). Furthermore, overexpression of miR-744 promoted tumor metastasis by suppressing PTEN and programmed cell death protein 4 pathways in laryngeal squamous cell carcinoma (12). However, other studies have suggested a role for miR-744 as a tumor suppressor rather than a dominant oncogene. miR-744 was downregulated and acted as a tumor suppressor in glioblastoma (24), gastric cancer (25) and colorectal cancer (26). Moreover, low expression of miR-744 has been implicated in the development and progression of liver cancer, and thus may be considered a potential prognostic marker in patients with hepatocellular carcinoma (27). Therefore, it is speculated that the dual roles of miR-744 may be attributed to the different cellular contexts and its interaction with target genes. Sun et al (11) revealed that miR-744 promoted osteosarcoma carcinogenesis by inhibiting the LATS2 signaling pathway. Furthermore, Sun et al (11) conducted cell viability, migration and invasion assays, and reported that miR-744 promoted cell viability and metastasis of osteosarcoma by suppressing LATS2 signaling. However, the biological functions and the underlying molecular mechanisms of miR-744 in osteosarcoma are not fully understood. Therefore, the present study investigated whether the oncogene miR-744 promoted osteosarcoma via a novel PTEN signaling pathway. The present study revealed that miR-744 was overexpressed in osteosarcoma tissues and cell lines, and also demonstrated that miR-744 promoted osteosarcoma cell proliferation via the suppression of PTEN expression. Thus, the present results may increase the understanding of the functional role of miR-744 in osteosarcoma, as it was indicated that miR-744 may primarily act as an oncogenic miRNA in osteosarcoma. However, whether miR-744 promotes cell migration and invasion of osteosarcoma via the PTEN pathway in vivo and in vitro requires further investigation.

PTEN is a tumor suppressor gene, and loss of its expression has been reported to be associated with growth and metastasis of various malignant tumors (13). PTEN deficiency may also result in activation of the PI3K/AKT signaling pathway, thus inhibiting apoptosis and promoting proliferation of tumor cells (16,28). Previous studies showed that the PTEN/PI3K/AKT signaling pathway was critical for carcinogenesis and progression in numerous cancer types, and AKT phosphorylation has been used as an indicator of activation of this pathway (29–31). Moreover, miR-744, acting as an oncogenic miRNA, has been reported to promote metastasis of laryngeal squamous cell carcinoma by suppressing PTEN expression and activating the PI3K/AKT signaling pathway (12). The present results indicated that miR-744 promoted cell proliferation in MG63 cells, which was associated with reduced PTEN expression and increased AKT phosphorylation. In addition, it was demonstrated that blocking the PI3K/AKT pathway with LY294002, an AKT inhibitor, abrogated the proliferative effect induced by miR-744. Therefore, the present results suggested that miR-744 increased osteosarcoma cell proliferation via the suppression of PTEN and subsequent activation of the PI3K/AKT pathway.

In conclusion, the present study demonstrated that miR-744 was overexpressed in osteosarcoma tissues and cells. miR-744 was suggested to have an active role in promoting cell proliferation via suppression of the PTEN signaling pathway (Fig. 5). These results may provide novel insights into the pathophysiological mechanism of osteosarcoma and facilitate the development of therapeutic targets for the treatment of this cancer type. However, there are some limitations to the present study. For example, this experiment was primarily conducted at the cellular level, and further in vivo studies are required to elucidate the role of miR-744 in osteosarcoma. Moreover, further experiments are required to investigate miR-744 regulation, as well as its underlying mechanisms in cell migration and invasion of osteosarcoma.

Figure 5. Schematic diagram of the mechanism of action of miR-744 in osteosarcoma cell proliferation. miR, microRNA.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Zhejiang Province Technology Project (grant no. 2015C33209) and the Wenzhou Technology Project (grant no. Y20150243).

Availability of data and materials

The datasets used and/or analyzed through the current study are available from the corresponding author upon reasonable request.

Authors' contributions

WY performed the majority of experiments and drafted the manuscript. PBC, FCC and SLD assisted with the experiments. WY and PBC analyzed the data and drafted the manuscript. WY and XYP conceived the study, supervised the experiments and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of The Second Affiliated Hospital, Wenzhou Medical University. Informed consent was obtained from the patients (age, ≥18 years) or their parents (patients aged <18 years).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References